Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer

Publisher： Karger

E-ISSN： 1423-0232|89|6|345-350

ISSN： 0030-2414

Source： Oncology, Vol.89, Iss.6, 2015-09, pp. : 345-350

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1671-1675

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 39-45

Karger

Access to resources Recommend Favorite

A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 75-82

Karger

Access to resources Recommend Favorite

Chemotherapy with Gemcitabine and Oxaliplatin in Patients with Advanced Biliary Tract Cancer: A Single-Institution Experience

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 311-315

Karger

Access to resources Recommend Favorite

Phase I study of gemcitabine, cisplatin, and S‐1 combination therapy for patients with untreated advanced biliary tract cancer

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 9, 2015-09 ,pp. : 669-674

John Wiley & Sons Inc

Access to resources Recommend Favorite